BRKR vs. PKI, AVTR, TXG, QTRX, MTD, ILMN, WAT, TECH, CRL, and BIO
Should you be buying Bruker stock or one of its competitors? The main competitors of Bruker include Revvity (PKI), Avantor (AVTR), 10x Genomics (TXG), Quanterix (QTRX), Mettler-Toledo International (MTD), Illumina (ILMN), Waters (WAT), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO).
Bruker (NASDAQ:BRKR) and Revvity (NYSE:PKI) are both computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
Revvity has a net margin of 28.94% compared to Bruker's net margin of 13.38%. Bruker's return on equity of 27.31% beat Revvity's return on equity.
Bruker currently has a consensus price target of $81.78, indicating a potential upside of 22.40%. Revvity has a consensus price target of $54.00, indicating a potential upside of ∞. Given Revvity's stronger consensus rating and higher possible upside, analysts clearly believe Revvity is more favorable than Bruker.
In the previous week, Bruker had 10 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Bruker and 0 mentions for Revvity. Revvity's average media sentiment score of 0.73 beat Bruker's score of 0.56 indicating that Revvity is being referred to more favorably in the news media.
Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Revvity pays an annual dividend of $0.28 per share. Bruker pays out 7.3% of its earnings in the form of a dividend. Revvity pays out 3.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Bruker has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Revvity has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
79.5% of Bruker shares are owned by institutional investors. Comparatively, 85.2% of Revvity shares are owned by institutional investors. 28.3% of Bruker shares are owned by company insiders. Comparatively, 0.5% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Bruker received 169 more outperform votes than Revvity when rated by MarketBeat users. Likewise, 64.83% of users gave Bruker an outperform vote while only 59.74% of users gave Revvity an outperform vote.
Revvity has higher revenue and earnings than Bruker. Revvity is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
Summary
Bruker beats Revvity on 10 of the 19 factors compared between the two stocks.
Get Bruker News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools